Evidence Table 120. KQ3—Dichotomous—Asparatate aminotransferase (AST) raised

| **Author Year**  **Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug**  **(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Davidson 200714  Parallel | > 3.0 x ULN | Unclear | Simvastatin (40) | Omega-3 | 122 | 0 | Placebo | 132 | 0 | NR |  | Medium |
| Napoli 199852  Parallel | Data imputed- there were no differences between baseline and post treatment values. | Unclear | Pravastatin (20-40) | Vitamin E |  | 0 | No Treatment |  | 0 |  | No differences in routine laboratory tests or adverse events were registered during the study in particular there were no differences between the values recorded in each individual after treatment compared to baseline values, and no differences between the treatment groups. | Medium |
| Chan 200212  Parallel | thresholds not specified | At moderate/moderately high risk for CHD (2+ risk factors) | Atorvastatin (40) | Omega-3 | 11 | 0 | No Treatment | 13 | 0 |  |  | Medium |
| Liu 200337  Parallel | thresholds not specified | Unclear | Simvastatin (10) | Omega-3 | 19 | 0 | No Treatment | 18 | 0 |  |  | Medium |

Evidence Table 120. KQ3—Dichotomous—Asparatate aminotransferase (AST) raised (continued)

| **Author Year**  **Study Design** | **Definition of outcome (if relevant)** | **CHD Risk Category** | **CVD drug**  **(dose mg/d))** | **Group 1: Name (supplement)** | **N1** | **N1 with event** | **Group 2: Name** | **N2** | **N2 with event** | **Estimates of Group Differences** | **Additional comments** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Young 200770  Parallel | > 3 times the upper level of normal | Mixed:  Mod and high risk | Simvastatin (10-40) | Co-Q10 | 22 | 0 | Placebo | 22 | 0 | NR | Exclusion criteria included: alanine aminotransferase or aspartate aminotransferase > 3 times the upper level of normal and results state: "Liver... function, …[was] not altered with either regime." Thus, counts of 0 and 0 were added for each arm | Medium |
| Gosai 200826  Crossover | reference range males: 0-46 U/L; females: 0-36 U/L | At low risk for CHD (0-1 risk factors) | Rosuvastatin (40) | Omega-3 | 48 | 0 | No Treatment | 48 | 2 |  | N/A | Medium |
| Di Spirito 200819  Crossover | N/A | At low risk for CHD (0-1 risk factors) | Atorvastatin (80) | Omega-3 | 50 | 9 | No Treatment | 50 | 13 |  | N/A | Medium |
| Balestrieri 19964  Crossover | N/A | Mixed:  Low and/or mod to high risk | Simvastatin (10-40) | Omega-3 | 14 | 0 | Placebo | 16 | 0 |  | N/A | Medium |
| Paolissa 199256  Crossover | N/A | At high risk for CHD | Nifedipine (88) | Vitamin E |  | 0 | Placebo |  | 0 |  | N/A | Medium |
| Watson 199966  Crossover | N/A | At high risk for CHD | ACE inhibitors (no description), furosemide, digoxin, also hydralazine and/or nitrates (NR) | Co-Q10 |  | 0 | Placebo |  | 0 | NR | N/A | Medium |